Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
14.96
-0.26 (-1.71%)
Sep 10, 2025, 2:50 PM - Market open
Amarin Corporation Revenue
Amarin Corporation had revenue of $72.74M in the quarter ending June 30, 2025, with 7.78% growth. This brings the company's revenue in the last twelve months to $219.36M, down -17.15% year-over-year. In the year 2024, Amarin Corporation had annual revenue of $228.61M, down -25.51%.
Revenue (ttm)
$219.36M
Revenue Growth
-17.15%
P/S Ratio
1.43
Revenue / Employee
$797,676
Employees
275
Market Cap
309.41M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 228.61M | -78.30M | -25.51% |
Dec 31, 2023 | 306.91M | -62.28M | -16.87% |
Dec 31, 2022 | 369.19M | -213.99M | -36.69% |
Dec 31, 2021 | 583.19M | -30.87M | -5.03% |
Dec 31, 2020 | 614.06M | 184.31M | 42.89% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AMRN News
- 10 days ago - Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 - GlobeNewsWire
- 11 days ago - New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups - GlobeNewsWire
- 16 days ago - New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025 - GlobeNewsWire
- 6 weeks ago - Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Amarin Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025 - GlobeNewsWire
- 2 months ago - RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE - GlobeNewsWire
- 4 months ago - Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript - Seeking Alpha